What is behind Metabolic Syndrome
Insulin sensitivity — how readily cells respond to insulin, the linchpin of metabolic health. Evidence B — Preclinical.
Fasting insulin — a sensitive marker of insulin resistance; chronically high levels signal metabolic strain. Evidence A — Human trial evidence.
The cell's master energy sensor — when fuel runs low it ignites fat-burning, glucose uptake and mitochondrial renewal while standing down growth. Evidence A — Human trial evidence.
Fatty-acid synthesis — the de-novo line that converts surplus carbohydrate into stored fat and liver triglyceride. Evidence A — Human trial evidence.
The mitochondrial pathway that dismantles fatty acids into cellular energy — the engine that empties stored and circulating fat. Evidence A — Human trial evidence.
The two-carbon unit every fuel converges on and every synthesis starts from. Evidence A — Human trial evidence.
The aggregate handling of fuel — glucose, fat and the hormones that route them, taken as one picture.
Evidence on these pathways
AMPK → Insulin Sensitivity. “In model systems, sustained decreases in AMPK activity accompany IR, whereas AMPK activation increases insulin sensitivity.” — AMPK, insulin resistance, and the metabolic syndrome. The Journal of Clinical Investigation, 2013, volume 123, issue 7, pages 2764-2772. doi:10.1172/JCI67227
Insulin Sensitivity → Women's Hormonal Balance. “A metabolic syndrome of obesity-related and/or intrinsic insulin resistance occurs in about half of PCOS patients, and the compensatory hyperinsulinism has tissue-selective effects, which include aggravation of hyperandrogenism.” — The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited. Endocrine Reviews, 2016, 37(5), 467-520. doi:10.1210/er.2015-1104
Insulin Sensitivity → Liver Integrity. “IR worsens NAFLD by increasing the accumulation of free fatty acids (FFAs) in the liver.” — Nonalcoholic fatty liver disease and type 2 diabetes: pathophysiological mechanisms shared between the two faces of the same coin. Exploration of Medicine, 2020, 1, 287-306. doi:10.37349/emed.2020.00019
Insulin Sensitivity → Micronutrient Status. “In diabetes, insulin resistance in renal tissue inhibits magnesium reabsorption and contributes to the hypomagnesemia observed in these patients.” — Hypomagnesemia With Metformin Use in Diabetes Mellitus: A Case and Narrative Review. Kidney Medicine, 2025, volume 7, article 101030. doi:10.1016/j.xkme.2025.101030
Formulas that act on these pathways
Acts on 7 of these pathways: Insulin Sensitivity, Fasting Insulin, AMPK, Fatty-Acid Synthesis, Fatty-Acid β-Oxidation, Acetyl-CoA, Metabolic Health.
Acts on 4 of these pathways: Insulin Sensitivity, Fasting Insulin, AMPK, Fatty-Acid β-Oxidation.
Acts on 4 of these pathways: Insulin Sensitivity, Fasting Insulin, AMPK, Fatty-Acid Synthesis.
Acts on 4 of these pathways: Insulin Sensitivity, Fasting Insulin, Fatty-Acid Synthesis, Fatty-Acid β-Oxidation.
Acts on 3 of these pathways: Insulin Sensitivity, AMPK, Fatty-Acid Synthesis.
Acts on 3 of these pathways: Insulin Sensitivity, AMPK, Fatty-Acid β-Oxidation.
What this page does not claim
This page names the pathways involved and the published evidence on each. It does not claim that any formula treats, cures or prevents Metabolic Syndrome. A pathway opens here only on graded, published evidence, under a standard fixed before the evidence was gathered, and every figure above carries its grade.
These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.